{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:46:11Z","timestamp":1782283571593,"version":"3.54.5"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cutaneous melanoma (CM) displays marked clinical heterogeneity and variable responses to immune checkpoint blockade (ICB). The CpG Island Methylator Phenotype (CIMP), characterized by widespread promoter hypermethylation, has been implicated in tumor progression, but its role in shaping the tumor immune microenvironment and therapeutic response remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DNA methylation and transcriptomic data from The Cancer Genome Atlas (TCGA) were analyzed and validated in an external cohort (GSE120878). Unsupervised clustering identified CIMP subtypes. Integrative analyzes included promoter-focused methylation\u2013expression coupling (ELMER), immune deconvolution (GSVA, MCPcounter, ESTIMATE), genomic profiling, and drug sensitivity prediction (GDSC). Clinical relevance was further assessed in an independent ICB-treated cohort (PRJEB23709). Functional assays evaluated the role of NRAS in melanoma cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two epigenetic subtypes were defined: CIMP+ (24.9%) and CIMP\u2212 (75.1%). CIMP+ tumors were associated with older age and male sex and exhibited significantly worse overall and progression-free survival, remaining an independent prognostic factor after multivariable adjustment. Integrative analysis identified 2,510 hypermethylated promoter probes linked to reduced expression of 1,707 genes enriched in interferon-\u03b3 and inflammatory pathways, although these associations likely reflect both tumor-intrinsic regulation and differences in cellular composition. Consistently, CIMP+ melanomas displayed an immune-depleted bulk-tumor profile, with reduced immune checkpoint gene expression, lower immune\/stromal scores, and decreased leukocyte-associated methylation signals. Genomically, CIMP+ tumors were enriched for NRAS and ARID2 mutations, showed fewer BRAF alterations, and exhibited significantly increased copy-number alterations and chromosomal instability. In an ICB-treated cohort, transcriptome-inferred CIMP+ status was significantly enriched in non-responders and associated with inferior survival. Drug sensitivity modeling identified multiple candidate compounds, including elesclomol and Wnt pathway inhibitors. Functionally, NRAS knockdown suppressed proliferation, migration, and invasion while promoting apoptosis and epithelial\u2013mesenchymal transition reversal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CIMP defines a clinically relevant melanoma subtype characterized by epigenetic remodeling, genomic instability, and an immune-poor tumor microenvironment, and is associated with poor prognosis and reduced benefit from immunotherapy. These findings suggest that therapeutic resistance in CIMP+ melanoma is multifactorial and highlight potential avenues for targeted intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1821360","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:46:07Z","timestamp":1782279967000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1512942","article-title":"Global, regional, and national burden of cutaneous Malignant melanoma from 1990 to 2021 and prediction to 2045","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2024.116129","article-title":"Changes in the surgical management of melanoma and measures to implement change","volume":"241","author":"McCahill","year":"2025","journal-title":"Am J Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2019-0022","article-title":"Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review","volume":"7","author":"Miller","year":"2020","journal-title":"Melanoma Manag"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.296","article-title":"Cutaneous adverse effects associated with LAG-3 inhibitor use in cancer treatment: A systematic review","volume":"3","author":"Ghani","year":"2023","journal-title":"Skin Health Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: Current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12967-021-03002-1","article-title":"Immune and stromal scoring system associated with tumor microenvironment and prognosis: a gene-based multi-cancer analysis","volume":"19","author":"Zeng","year":"2021","journal-title":"J Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13237-021-00367-y","article-title":"DNA methylation and regulation of gene expression: Guardian of our health","volume":"64","author":"Dhar","year":"2021","journal-title":"Nucleus (Calcutta)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2018.01.020","article-title":"Epigenetic regulation by CpG methylation splits strong from retarded IFNgamma-induced IL-18BP in epithelial versus monocytic cells","volume":"1861","author":"Bachmann","year":"2018","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"B12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10142-025-01552-x","article-title":"Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases","volume":"25","author":"Zahoor","year":"2025","journal-title":"Funct Integr Genomics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"10674","DOI":"10.3390\/ijms221910674","article-title":"Bona fide tumor suppressor genes hypermethylated in melanoma: a narrative review","volume":"22","author":"Guvenc","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41420-025-02751-y","article-title":"The dark side of the light (UVA): melanoma microenvironment and cell survival strategies","volume":"11","author":"Basu","year":"2025","journal-title":"Cell Death Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/srep02962","article-title":"Genome-wide methylated CpG island profiles of melanoma cells reveal a melanoma coregulation network","volume":"3","author":"Li","year":"2013","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.11.017","article-title":"Characterization of the CpG island hypermethylated phenotype subclass in primary melanomas","volume":"142","author":"Conway","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2015-2972","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12064-012-0162-3","article-title":"Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples","volume":"131","author":"Wagner","year":"2012","journal-title":"Theory Biosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.11.024","article-title":"Identification of a robust methylation classifier for cutaneous melanoma diagnosis","volume":"139","author":"Conway","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts034","article-title":"The sva package for removing batch effects and other unwanted variation in high-throughput experiments","volume":"28","author":"Leek","year":"2012","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btx513","article-title":"ChAMP: updated methylation analysis pipeline for Illumina BeadChips","volume":"33","author":"Tian","year":"2017","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw967","article-title":"Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes","volume":"45","author":"Zhou","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-587","article-title":"Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis","volume":"11","author":"Du","year":"2010","journal-title":"BMC Bioinf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202103557","article-title":"Exceptional electrochemical HER performance with enhanced electron transfer between Ru nanoparticles and single atoms dispersed on a carbon substrate","volume":"60","author":"Su","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"B26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1113-y","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci91095","article-title":"DNA methylation-based immune response signature improves patient diagnosis in multiple cancers","volume":"127","author":"Jeschke","year":"2017","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv560","article-title":"missMethyl: an R package for analyzing data from Illumina's HumanMethylation450 platform","volume":"32","author":"Phipson","year":"2016","journal-title":"Bioinformatics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","article-title":"Gene set knowledge discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr Protoc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty902","article-title":"ELMER v.2: an R\/Bioconductor package to reconstruct gene regulatory networks from DNA methylation and transcriptome profiles","volume":"35","author":"Silva","year":"2019","journal-title":"Bioinf (Oxford England)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-3-r47","article-title":"Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines","volume":"15","author":"Geeleher","year":"2014","journal-title":"Genome Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-0634-7","article-title":"Efficient metal ion sieving in rectifying subnanochannels enabled by metal-organic frameworks","volume":"19","author":"Lu","year":"2020","journal-title":"Nat Mater"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.15.297820","article-title":"MOVICS: an R package for multi-omics integration and visualization in cancer subtyping","volume":"36","author":"Lu","year":"2021","journal-title":"Bioinformatics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.034","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-22539-5_1","article-title":"Heterogeneity in melanoma","volume":"167","author":"Shannan","year":"2016","journal-title":"Cancer Treat Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/s41467-022-30881-9","article-title":"Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation","volume":"13","author":"Murphy","year":"2022","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2026.1873649","article-title":"Editorial: New tumor immune checkpoints and their applications in tumor immunotherapy","volume":"13","author":"Zhang","year":"2026","journal-title":"Front Mol Biosci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108640","article-title":"Therapeutic targeting of DNA methylation alterations in cancer","volume":"258","author":"Lee","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148-025-01865-5","article-title":"DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities","volume":"17","author":"Deshmukh","year":"2025","journal-title":"Clin Epigenet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007736","article-title":"Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance","volume":"11","author":"James","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/s41598-024-54136-3","article-title":"ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes","volume":"14","author":"Akinjiyan","year":"2024","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02176-2","article-title":"BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage","volume":"41","author":"He","year":"2022","journal-title":"Oncogene"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: Towards\u00a0better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002226","article-title":"DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma","volume":"9","author":"Filipski","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217432","article-title":"Mechanisms of low MHC\u00a0I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy","volume":"611","author":"Kong","year":"2024","journal-title":"Cancer Lett"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.06.003","article-title":"DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer","volume":"36","author":"Ricciuti","year":"2025","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41467-024-46422-5","article-title":"Mi-2\u03b2 promotes immune evasion in melanoma by activating EZH2 methylation","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.044174","article-title":"LncRNA HOTAIR promotes DNA damage repair and radioresistance by targeting ATR in colorectal cancer","volume":"32","author":"Hu","year":"2024","journal-title":"Oncol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf178","article-title":"Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic","volume":"193","author":"Wang","year":"2025","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:46:08Z","timestamp":1782279968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2026.1821360"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1821360","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1821360"}}